GABAPENTIN | A075360 | GRANULES INDIA LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition Amendment from Rising Pharma Holdings, Inc. FDA-2026-P-5123 · 6 docket documents Rising Pharma Holdings, Inc. filed this amendment to suitability petition FDA-2026-P-5123 on June 4, 2026, in response to an FDA information request dated May 28, 2026, regarding Gabapentin Capsules, 150 mg, for which the company initially sought permission to file an ANDA. The company provided the | Suitability | 2026-06-05 | Open | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0410
per ea
Lowest NADAC/Unit
$0.0210
per ea
Brand NDCs
0
Generic NDCs
8
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70010092801GABAPENTIN 400 MG CAPSULE | $0.0410 | EA | Generic | — | 2026-06-17 |
| 70010092805GABAPENTIN 400 MG CAPSULE | $0.0410 | EA | Generic | — | 2026-06-17 |
| 70010092705GABAPENTIN 300 MG CAPSULE | $0.0324 | EA | Generic | — | 2026-06-17 |
| 70010092701GABAPENTIN 300 MG CAPSULE | $0.0324 | EA | Generic | — | 2026-06-17 |
| 70010092710GABAPENTIN 300 MG CAPSULE | $0.0324 | EA | Generic | — | 2026-06-17 |
| 70010092605GABAPENTIN 100 MG CAPSULE | $0.0210 | EA | Generic | — | 2026-06-17 |
| 70010092610GABAPENTIN 100 MG CAPSULE | $0.0210 | EA | Generic | — | 2026-06-17 |
| 70010092601GABAPENTIN 100 MG CAPSULE | $0.0210 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.